AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02796456 — intervention group
Intervention type: OTHER
Intervention: blood sample
Study NCT02196532 — intervention group
Intervention type: DEVICE
Intervention: Device: Optical coherence tomography
Study NCT04243486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UHE-105
Description: Topical shampoo containing active drug
Study NCT04243486 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Topical shampoo containing no active drug
Study NCT04353687 — intervention group
Intervention type: DEVICE
Intervention: Robotic-assisted inguinal hernia repair
Description: Each surgeon will perform the robotic-assisted inguinal hernia procedure per their standard practice. Surgeon subjects will consent to prospectively provide selected procedure and case data.
Study NCT03981276 — intervention group
Intervention type: OTHER
Intervention: Clinical rating scale to measure disease severity and progression
Description: A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.
Study NCT03981276 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Next-Gen Sequencing (NGS)
Description: Whole Genome Sequencing, Whole Exome Sequencing, Transcriptomics, Proteomics, Metabolomics
Study NCT00566904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epikeia coatings with lidocaine
Description: Applied to affected skin area using a roll-on ball applicator
Study NCT00566904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epikeia coatings alone
Description: Applied to affected skin area using a roll-on ball applicator
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Meet with exercise physiology
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Receive prescription for moderate aerobic exercise
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiological Support
Description: Receive motivational support via telephone care
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03641287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo habitual level of physical activity
Study NCT02398019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXIRIS®
Description: OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[OXIRIS® (Baxter Gambro)\].~PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.~OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time.
Study NCT01668680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPECITABINE, CELECOXIB and METHOTREXATE
Description: daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IV, IM, or PO
Study NCT03441204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTOT 24 h/day
Description: LTOT prescribed for 24 h/day.
Study NCT03441204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LTOT 15h/day
Description: : LTOT prescribed for 15 h/day. The patient is instructed to use LTOT during sleep and not to use LTOT for about 9 hours during daytime, totalling 15 h/day.
Study NCT02880241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048
Description: Tablets of 20mg each
Study NCT00084903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colposcopic biopsy
Description: Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
Study NCT00557193 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Asparaginase
Description: Given IV, IM, or PO
Study NCT00084903 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Light-Scattering Spectroscopy
Description: Spectroscopy readings taken in 2 regions of cervix.
Study NCT01901510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chromoendoscopy (Indigo Carmine)
Description: Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
Study NCT01901510 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
Study NCT00557193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04054635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Antibiotic liquid with anti-caries effects. A non-restorative option to manage cavitated caries lesions. Approved for clinical use in Canada in 2017.
Study NCT04584099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency device treatment
Description: TempSure firm
Study NCT01911169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 5,000 International units versus 400 international units as an active comparator
Study NCT01911169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 5,000 International units versus 400 international units as an active comparator
Study NCT03420209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group applying PNF technique
Study NCT03189316 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: peritoneal fluid and blood sample
Description: Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
Study NCT02789917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual Therapy
Description: Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
Study NCT02789917 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Triple Therapy
Description: HAS-BLED-Score \<3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.~HAS-BLED-Score ≥ 3:~Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months.
Study NCT03053388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Nitric Oxide given via inhalation in cycles
Study NCT03053388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive treatment
Description: Supportive treatment (including oxygen)
Study NCT03053388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive treatment
Description: Supportive treatment (including oxygen)
Study NCT00891930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
Study NCT00891930 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ganitumab
Description: AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
Study NCT00891930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
Study NCT03098810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulphate
Description: Oral syrup zinc sulphate
Study NCT03098810 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral syrup placebo
Study NCT01801878 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline inject to the half of irradiated breast
Study NCT05737173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte-rich platelet-rich plasma
Description: Intra-articular knee injection
Study NCT05737173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leukocyte-poor platelet-rich plasma
Description: Intra-articular knee injection
Study NCT02045836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT02045836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herpes Zoster vaccine GSK 1437173A
Description: 2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT05737173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Intra-articular knee injection
Study NCT01988688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Description: Deep Brain Stimulation (DBS) bilaterally in area LC.
Study NCT01960400 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) (active or placebo)
Description: TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
Study NCT01960400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS) (active or placebo)
Description: TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
Study NCT01960400 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Graded motor imagery (GMI)
Description: The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
Study NCT01960400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Graded motor imagery (GMI)
Description: The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
Study NCT02410850 — intervention group
Intervention type: DEVICE
Intervention: Oral Appliance
Description: Mandibular Advancement Splints
Study NCT02138682 — intervention group
Intervention type: DRUG
Intervention: l-123 Ioflupane
Description: 5 millicuries of Ioflupane
Study NCT02368015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral intravenous cannula (IVC)
Description: Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
Study NCT01321931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 6 mg experimental Nicotine Replacement Therapy (NRT)
Study NCT02045836 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Description: One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT02045836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Description: One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
Study NCT02368015 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cefazolin
Study NCT02487667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic exercise by fitness machines
Description: Therapeutic exercise program by using 8 exercise machine circuit
Study NCT01130454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Universal Electrophysiological Biofeedback Treatment
Description: one 45 minute biofeedback treatment
Study NCT01130454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Universal Electrophysiological Biofeedback Treatment
Description: one 45 minute placebo treatment
Study NCT04094883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B Vaccine
Description: All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.
Study NCT04075760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coils + Cyanoacrylate Group + beta-blocker
Description: EUS-combined coiling and cyanoacrylate injection into the feeder vessel of GOV II and IGV I~Patients with Gastric Varices GOV II or IGV I that have never bleed and are of high-risk GV according to Baveno VI consensus will be prophylactically obliterated via the EUS-guided coiling and cyanoacrylate injection. Patients will also be on beta-blocker therapy as indicated in the other group.
Study NCT04075760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: beta blocker therapy
Description: A beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was > 90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure \< 90 mm Hg or pulse rate \< 55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
Study NCT01321931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 4 mg marketed Nicotine Fruit Gum (NFG)
Study NCT01321931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 4 mg marketed nicotine mint lozenge (NIQ)
Study NCT00509496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: 25 mg/m\^2/day intravenous piggy back over 30 minutes for 5 days.
Study NCT00509496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenous
Study NCT00509496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: 720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
Study NCT02341625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986148
Study NCT00509496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes
Description: Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered TIL .~The cells are infused intravenously over 20-30 minutes.
Study NCT02341625 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT04838158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Isokinetic measurements
Description: Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
Study NCT04838158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Isokinetic measurements
Description: Each patient underwent an isokinetic examination on Biodex System 3 (Biodex Multi-Joint System - Pro, Biodex Medical Systems, Inc. New York, USA). In the study group, both side hamstring muscle were evaluated at the velocities of 60 and180 deg/s for the following parameters: peak torque (PT), torque in 30 degree of the knee flexion (T 30 deg.), angle of peak torque (APT) and peak torque hamstring to quadriceps ratio (H/Q ratio).
Study NCT01430858 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Strain Gauge
Description: The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
Study NCT00509496 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes
Description: Patients will receive a minimum of approximately 5 X 10\^8 cells and up to 3 x10\^11 anti-gp100:154-162 TCR engineered PBL.~The cells are infused intravenously over 20-30 minutes.
Study NCT02643186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: preoperative vaginal misoprostol
Description: preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
Study NCT02643186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral uterine artery ligation
Description: bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
Study NCT04086069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sit-to-stand trainer
Description: The sit-to-stand trainer device is an exoskeleton that enables standing-up movement resembling the movement of a healthy person. It consists of three sub-systems: a foldable chair, a lever for body orientation and a triggering mechanism. It includes a support for feet with adjustable height. The device offers partial support to the patient while standing up. The patient will exercise with the device for 10 sessions (one per day), standing up for up to 30 times per session.
Study NCT00914602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet 25-100 Oral Tablet
Description: After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days.
Study NCT00914602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP21279
Description: Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
Study NCT00914602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Pill